Figure 9.

YYD inhibits NSCLC tumor growth. A549 cells were subcutaneously implanted into nude mice to establish the transplantation tumor models of NSCLC. After 6 days, mice were intragastrically administered with YYD daily. (a) Tumor growth was examined every 3 days. (b) Tumor weight. (c) The expression of proteins associated with EGFR-PI3K-AKT signaling. (d) IHC staining for p-EGFR, Ki-67, cyclin D1, and Bax in xenograft tumors. ^∗p < 0.05, ^∗∗p < 0.01, and ^∗∗∗p < 0.001 versus the control group.